B
eing born small for gestational age (SGA) has been associated with problems in health-related quality of life (HRQoL), behavior, and cognitive development (1) (2) (3) (4) (5) (6) . In short SGA children without sufficient catch-up growth, long-term continuous recombinant GH treatment leads to an improvement in adult height (AH) (7) (8) (9) . Additional gonadotropin-releasing hormone analog (GnRHa) treatment of 2 years at the start of puberty increases AH in both boys and girls who start GH treatment at the onset of or in early puberty with an expected AH of ,22.5 standard deviation score (SDS) (10) .
GnRH influences structures outside the pituitary region, in the hippocampus and other limbic structures (11) (12) (13) . GnRHa treatment may therefore have cognitive effects, as has been shown during 2 years of GnRHa treatment in precocious puberty. Cognitive functioning at cessation of GnRHa treatment tended to be lower in the group receiving 2 years of GnRHa treatment (14, 15) . However, it is unknown whether GnRHa treatment affects long-term cognitive functioning.
Short stature has a negative effect on HRQoL, and GH treatment improves HRQoL (16) (17) (18) (19) . We have shown that 2 years of GnRHa in addition to GH treatment did not have adverse effects on HRQoL in children born SGA during 2 years of treatment (20) . However, the postponement of puberty might negatively affect problem behavior and school skills later in life (21) . Furthermore, GnRHa treatment has been linked to a suppressed reward system, causing subsequent depressive emotions when used for endometriosis and during fertility treatment. However, these populations differed greatly from children who receive GnRHa treatment of the purpose of postponing puberty (15, 22) . Data on the long-term effects of pubertal suppression-by means of 2 years of GnRHa in addition to GH treatment-on HRQoL, selfperception, and problem behavior in early adulthood are lacking.
The primary objective of this study was to assess cognitive functioning and HRQoL after attainment of AH in subjects who participated in Dutch GH trials involving children born SGA treated with GH, either with or without additional 2 years of GnRHa treatment after onset of puberty. In addition, we tested selfperception and problem behavior in these subjects, to evaluate psychosocial functioning at AH.
We hypothesized that postponement of puberty by 2 years of GnRHa treatment in GH-treated young adults born SGA does not negatively influence cognitive functioning, HRQoL, self-perception, or problem behavior in early adulthood compared with GH treatment only. Additionally, we hypothesized that AH would positively correlate with HRQoL and self-perception and negatively with problem behavior and that a double GH dosage of 2 mg/m 2 /d (~0.067 mg/kg/d) would not influence these outcomes.
Method

Subjects
The study group consisted of young adults born SGA who had participated in the Dutch SGA trial (ISRCTN18062389) (study group 1). SGA was defined as birth weight or birth length ,-2 SDS for gestational age, with a height at start of GH treatment ,22.5 SDS and no endocrine, metabolic, or chronic disorders. GH treatment was started at $8 years and continued until attainment of AH. Study group 1 consisted of 99 GHtreated young adults who either additionally received GnRHa treatment of 2 years (n = 61; GH/GnRHa) or received only GH treatment (n = 38; GH). The 2 years of GnRHa treatment was prescribed when height at the start of puberty would result in an expected AH ,22.5 SDS, based on Dutch references (23) . At the start of puberty, subjects were randomly assigned to treatment with GH either 1 or 2 mg/m 2 /day (~0.033 or 0.067 mg/kg/d) after stratification for sex, pubertal stage, and parental height.
For the evaluation of self-perception and problem behavior only, we added 67 young adults born SGA from the intrauterine growth retardation-3 study (ISRCTN65230311) (study group 2). These subjects started GH treatment at the age of 5 to 8 years, and 19 subjects received 2 years of GnRHa treatment in addition to GH treatment if they met the same inclusion criteria used in study group 1. The treatment regimens of both studies and the number of subjects per completed test by the study groups are shown in an online repository (24, 25) .
The Medical Ethics Committee of the Erasmus University Medical Center approved both studies. We obtained written informed consent from all subjects and, if they were ,18 years old, from their parents or guardians. Because of ethical considerations, the medical ethics committee did not allow a randomly assigned untreated short SGA group.
Measurements
At the start, every 3 months during GH treatment, and at AH, height was measured to the nearest 0.1 cm with a Harpenden stadiometer (Holtain, Ltd., Crymmyth, UK). Height was transformed into SDS for sex and chronological age according to Dutch references, with Growth Analyzer Research Calculation Tools (Growth Analyzer B.V., Rotterdam, Netherlands). AH SDS was calculated with references for Dutch adults aged 18 years (23).
Socioeconomic status
Parents provided information about their socioeconomic status (SES) by means of a questionnaire at the start of GH treatment. The highest of two education levels (father and mother) was used as socioeconomic indicator to determine SES (categorized as 1 = lowest, 2 = low, 3 = medium, and 4 = high) (26) .
Cognitive functioning
To assess cognitive functioning, the Wechsler Adult Intelligent Scale-Third Edition (WAIS-III) was performed in 86 subjects to obtain the IQ. The Wechsler Intelligence Scale for Children-Third Edition (WISC-III) was administered to 13 subjects who attained AH before 16 years of age (27, 28) . All tests were performed by an experienced psychologist in adherence to the standardization instructions of the WAIS-III and WISC-III manual, within a quiet area to minimize distraction during testing.
Both tests consist of 11 subtests (Picture Completion, Vocabulary, Digit Symbol Coding, Comprehension, Symbol Search, Similarities, Information, Digit Span, Letter-Number Sequencing, Block Design, Matrix Reasoning), from which we created the total IQ, performance IQ, and verbal IQ, as described by the WAIS-III and WISC-III manuals (27, 28) . There is a good correlation between the WAIS-III and WISC-III IQ scores (r = 0.88, r = 0.78, and r = 0.88 for total IQ, performance IQ, and verbal IQ, respectively) (29).
HRQoL
When subjects had attained AH at or at 16 years or older, the validated TNO-AZL Questionnaire for Adult's Health-Related Quality of Life (TAAQOL) was completed to assess HRQoL (30, 31) . The TAAQOL consists of 45 items and contains 12 scales (gross motor function, fine motor function, cognitive functioning, sleep, pain, social functioning, daily activities, sexuality, vitality, positive emotions, depressive emotions, and aggressive emotions). Most items consist of two questions. The first question assesses whether a participant has experienced a health status limitation in the last couple of weeks. If present, the second question evaluates the emotional feeling about this limitation. The scale scores are obtained by combining both responses into one HRQoL score per item, adding item scores within scales and transforming crude scale scores to a 0 to 100 scale. Higher scores indicate a better HRQoL. This questionnaire specifically offers the subjects the ability to differentiate between their functioning and the way they feel about it.
We excluded the questions about sexuality in our analysis because most subjects replied they were not able to answer these questions. Thirteen subjects could not complete the TAAQOL questionnaire because they were not yet 16 years of age.
Based on the data of the Dutch population, Cronbach a values ranging from 0.65 to 0.84 indicated that comparisons on group level were justified (32) , and the psychometric properties, reliability, and validity of this questionnaire were satisfactory (30) .
As recommended in the TAAQOL manual, 103 healthy respondents in the same age range of 16 to 22 years in study group 1 were selected from the total reference group (n = 4410) and included in the analyses (30).
Self-perception
Subjects in study groups 1 and 2 completed the validated Dutch version of the Self-Perception Profile of Adolescents (CBSA) at attainment of AH (33, 34) . This questionnaire comprises seven domains: School Skills, Social Acceptance, Sports Skills, Physical Appearance, Behavioral Attitude, Feeling of Self-Esteem, and Friendship. Each domain consists of five items consisting of two propositions; subjects can indicate which proposition suits them the most. The questionnaire uses a 4-point Likert scale. Results are presented as rank percentiles, compared with a reference population, corrected for level of education and sex. Cronbach a values were mostly~0.80 for each domain. The test-retest reliability correlations of this questionnaire were highly significant (r = 0.72 to 0.76; P , 0.01) (34) .
Problem behavior
Parents of study groups 1 and 2 completed the Child Behavior Check List (CBCL) and Adolescent Behavior Check List (ABCL) at attainment of AH. The questionnaire consists of 113 questions on specific problem behavior, scored on a 3-point Likert scale (0 indicating absent behavior, 2 indicating behavior is frequently present). This questionnaire is one of the most widely used dimensional rating scales of psychopathology, because it rates behavior on three main scales (total problems, externalizing problems, and internalizing problems) and eight subscales (withdrawn behavior, somatic complaints, anxious/depressed behavior, social problems, thought problems, attention problems, delinquent behavior, and aggressive behavior) (35) . Raw scores are continuous and can be transformed into standardized T-scores, with a mean of 50 and a standard deviation of 10, compared with a reference population. This questionnaire has been studied extensively in clinical and community populations (36) (37) (38) .
Data analysis
All tests were performed in the statistical package SPSS version 24.0 (SPSS Inc., Chicago, IL) for Windows. Clinical characteristics are presented as mean (SD) unless stated otherwise. Distribution of variables was determined by Kolmogorov-Smirnov test and normal Q-Q plots. Differences in characteristics between the groups were tested with the Student t test for continuous variables and x 2 test for proportions. Nonparametric variables of the TAAQOL questionnaire were tested by means of the MannWhitney U test and the Kruskal-Wallis test.
We used the Pearson correlation and Spearman rank order correlation (r) to calculate the strength of the relationship between the outcomes of the questionnaires and adult height. Differences between the 1-and 2-mg/m 2 /d GH dosage groups in all questionnaires were evaluated with an independent-sample t test. Results were regarded as statistically significant at a P of , 0.05. Table 1 shows the clinical characteristics of study group 1 at start and cessation of GH treatment. In total, 99 (61 GH/GnRHa, 38 GH) subjects completed the questionnaires at AH, on average 3.48 years after cessation of GnRHa treatment. In the GH/GnRHa and GH groups, mean (SD) age at start of GH treatment was 11.98 (1.72) vs 11.19 (2.26) years in male and 11.63 (1.05) vs 10.27 (1.15) years in female subjects (P , 0.001), respectively. At cessation of GH treatment, mean (SD) age was 18.35 (0.79) vs 18.28 (1.19) years in male and 16.88 (1.02) vs 16.24 (0.93) in female subjects (P = 0.009), in the GH/GnRHa and GH groups, respectively. Mean SES was significantly higher in subjects who additionally received GnRHa treatment (P = 0.016). Table 2 shows the mean (SD) scores in the GH/GnRHa and GH group on total, performance, and verbal IQ scores in the 99 subjects of study group 1 only. Total IQ scores were not significantly different between the GH/GnRHa group and GH group (96.33 vs 92.47, respectively; P = 0.135). Also, the performance and verbal IQ scores were not significantly different (P = 0.280 and P = 0.198, respectively). The total IQ, performance IQ, and verbal IQ scores were similar between GH dosage groups.
Results
Clinical characteristics
Cognitive functioning
Cognitive functioning correlated significantly with SES (r = 0.495, P = 0.001), but within each category of SES, cognitive functioning was similar in the GH/GnRHa and GH groups.
The GH/GnRHa and GH groups had significantly lower cognitive functioning when compared with the reference population (94.85 vs 100.00, respectively; P = 0.001). However, their cognition was still within the normal ranges. Although the difference was not significant, total IQ scores were higher in the GH/GnRHa group. This difference disappeared after correction for socioeconomic status (P = 0.554). Table 3 shows the mean (SD) TAAQOL scores at GH cessation in the GH/GnRHa and GH groups of study group 1 and of an age-matched reference population.
HRQoL
Subjects who additionally received GnRHa treatment had a significantly higher quality of life regarding positive emotions when compared with the GH group (76.63 vs 66.39, respectively; P = 0.039), also after correction for SES (P = 0.028).
Depressive emotions were similar in both groups, and none of the subjects received antidepressant therapy. No significant correlations with AH were found in all HRQoL categories in the GH/GnRHa and GH groups. HRQoL scores were similar in both GH dosage groups. However, cognitive functioning was perceived significantly differently among the GH/GnRHa group, GH group, and reference population (P = 0.002). The GH/ GnRHa group had lower perceived cognitive functioning than the reference population (78.42 vs 87.86, respectively; P = 0.002), whereas the GH group had a trend toward lower perceived cognitive functioning compared with the reference population (82.76 vs 87.86, respectively; P = 0.176). There was no significant difference in perception of cognitive functioning between the GH/GnRHa and GH groups (P = 0.422).
Self-perception
The self-perception questionnaire was completed by 142 young adults in study groups 1 and 2. The results are presented in Table 4 , with higher scores indicating better self-perception. No significant differences were found between the GH/GnRHa and GH groups. Compared with the reference population, both groups scored significantly better for behavioral attitude, +0.57 SDS for GH/GnRHa and +0.68 SDS for GH (P , 0.001). No significant correlations were found between AH and self-perception scores in the GH/GnRHa and GH groups. Self-perception was similar in both GH dosage groups. 
Problem behavior
The ABCL and CBCL questionnaires, completed by 136 parents of study groups 1 and 2, did not show any significant differences between the GH/GnRHa and GH groups and the reference population. Results are presented in Table 5 , with lower scores representing less problem behavior. Total problem scores were similar, being 49.36 and 49.62 in the GH/GnRHa and GH groups, respectively. Externalizing problems and internalizing problems were also similar in both groups. AH did not significantly correlate with total problem scores (r = 20.33; P = 0.714) or with any other problem behavior score in the GH/GnRHa and GH groups. At AH, problem behavior was similar in both GH dosage groups.
Discussion
We assessed cognitive functioning, HRQoL, self-perception, and problem behavior in young adults born SGA who received GH treatment and an additional 2 years of GnRHa treatment, compared with GH treatment only. At AH, fullscale IQ, verbal IQ, and performance IQ scores were similar in the GH/GnRHa and GH groups. Compared with the reference population, the GH/GnRHa and GH group scored themselves significantly lower in their perception of cognitive functioning. However, all other categories showed similar results in both groups. At AH, self-perception and problem behavior were similar in both groups and compared with the reference population. AH did not correlate with HRQoL, self-perception, and problem behavior scores, and all scores were similar between GH dosage groups.
Cognitive functioning, as measured by the WAIS-III and WISC-III tests, was similar in the GH/GnRHa and GH groups. This is a reassuring result, because cognitive function after GnRHa treatment has been subject of concern. Two earlier studies showed a lower cognitive functioning at cessation of GnRHa treatment when compared with the start of treatment, based on the results of the WAIS test (14, 15) . Our results show that this effect is not present at AH. The lower scores found in the other studies probably reflect the delay in psychosocial maturation at time of testing, because GnRHa-treated patients entered puberty later than their peers. Cognitive functioning in the GH/GnRHa and GH groups was The TAAQOL questionnaire was completed by subjects at AH. Scores are expressed as mean (SD). Higher scores indicate better quality of life. Bold P values are considered significant differences between groups. Self-perception questionnaire (CBSA) was filled in by subjects and compared with the reference population provided by the questionnaire. No significant differences were found between groups. a Significantly higher than in reference population used in the questionnaire.
below the mean of the reference population but still within the normal ranges. This finding is in line with other studies describing lower cognitive functioning in SGA children (39) (40) (41) (42) . SES, as defined by parental education levels, had a strong correlation with cognitive functioning. Total IQ scores tended to be higher in the GH/GnRHa group, but when corrected for SES, GnRHa treatment did not show a long-term effect on cognitive functioning.
HRQoL is important as a patient-reported outcome because it reflects the subjective perception of health. Young adults in the GH/GnRHa group perceived a lower HRQoL in cognitive functioning compared with the GH group and the reference population, with the GH/GnRHa group scoring lowest, followed by the GH group. This finding is in contrast to the slightly higher cognitive function in the GH/GnRHa group. Because the GH/GnRHa group had a higher SES, it might be that the young adults underrated their cognitive functioning because they compared themselves with their better-performing parents.
Some studies suggest an increase in depressive emotions after GnRHa treatment of pubertal suppression or other indications (15, 22) . Our long-term results are reassuring because they show that 2 years of GnRHa treatment does not increase depressive emotions in young adults born SGA.
The CBSA questionnaire was created to specifically measure feelings of self-perception in specific domains and global self-perception. These domains of self-perception are of great importance, because they reflect the concerns of young adults about job competence, dating, and close friendships (33, 34) . In our study, self-perception scores were similar in the GH/GnRHa and GH-treated groups and also compared with the reference population. Our results are in line with two studies describing no decrease in CBSA scores during 3 years of GnRHa treatment (14, 43) . To our knowledge, no long-term studies were performed on self-perception in young adults many years after GnRHa treatment.
Internalizing, externalizing, and total problem behaviors were not significantly different between young adults in the GH/GnRHa and GH groups and compared with the reference population. Normal behavior after 3 years of GH and GnRHa treatment in children with precocious puberty after adoption has been reported (44) . Studies found no difference in problem behavior in untreated children with short stature after SGA birth or due to idiopathic short stature, when compared with the reference population (14, 15, 43) . The comparison with the reference population is likely to overestimate the problem scores in our population, because subjects who visited a mental health professional in the last 12 months or had received extra educational support were excluded from the reference population (45) . However, mean problem scores of our study group were not significantly higher than those of the healthy reference population, which underlines the normal problem behavior in our study groups.
Subjects who received a double GH dosage of 2 mg/ m 2 /d had similar outcomes in cognitive function, HRQoL, self-perception, and problem behavior at AH. We did not find a correlation between AH and HRQoL, self-perception, or problem behavior, which suggests that there is no causal relation between AH and these psychosocial functioning scores. This outcome has also been described in children with untreated short stature (42, 46) . However, the lack of correlation in this study might also be explained by the limited variation in adult height in our study groups, as Bannink et al. (17) reported an increase in HRQoL in GH-treated subjects born SGA, in parallel to the increase in height. The growth characteristics were similar in study groups 1 and 2 (10, 47, 48). Our study did not have a randomized placebo group because pubertal development will continue during placebo treatment, which will be visible for the patient and the physician. The aim of the current study was to compare GnRHa/GH and GH effects on cognitive functioning and HRQoL and not on growth. The effectiveness and safety of the combined GH/GnRHa treatment on growth have been described in earlier reports about the Dutch SGA study, based on a slightly smaller study population. GnRHa treatment in addition to GH treatment resulted in significantly greater height gain and AH in early pubertal children with a poor AH (10) . Results on bone mineral density, body composition, and cardiovascular and metabolic health have been published, showing that an additional 2 years of GnRHa treatment is effective and safe (49) (50) (51) .
In conclusion, our study shows that 2 years of GnRHa treatment in addition to GH treatment results in similar cognitive functioning, HRQoL, self-perception, and problem behavior compared with GH treatment only in young adults born SGA. In contrast to our hypothesis, no significant correlations were found between AH and problem behavior and self-perception scores. Based on our results, additional GnRHa treatment could be considered at the start of puberty for GH-treated children born SGA with an AH prediction ,22.5 SDS.
